Pluri Inc.
PLUR · NASDAQ
Market closed$1.86$0.060000 (+3.33%)After hours $1.86 · 0.00%
Key statistics
Previous close$1.80
Open$1.86
Day high$2.01
Day low$1.82
52-week high$5.68
52-week low$1.56
Market cap16.72M
Volume37.33K
Average volume22.51K
P/E ratio-0.41
Forward P/E—
EPS-4.53
Dividend yield0.00%
Market context
Why it moved
PLUR edged higher amid a surge in rave culture visibility and social media buzz, with posts celebrating PLUR (Peace, Love, Unity, Respect) values at live events appearing on July 18, 2026, potentially drawing renewed investor attention to the stock.
What is happening
Recent company-specific developments and publisher coverage.
CTech · July 16, 2026Once worth NIS 1 billion, Pluri is now racing to avoid Nasdaq delistingGuruFocus · July 15, 2026Pluri's Chairman Increases Investment and Ownership Stake (PLUR)Stock Titan · July 14, 2026Pluri Chairman Builds 30%-Plus Position With $17M InvestmentTradingView · July 13, 2026Pluri Disclosed Failure to Satisfy a Continued Listing Rule or StandardInvesting.com · June 1, 2026Pluri Inc. and European Investment Bank continue loan discussions, no enforcement action expected before JulyContract Pharma · February 18, 2026Pluri Biotech Secures China Patent for Immune Cell Techi24NEWS · February 17, 2026Pluri's Cell Therapy To Extends Lifespan And Combat Chronic Disease Benzinga · July 14, 2026Pluri Announces Chairman Alejandro Weinstein Has Invested $17M+In PLUR, Including A $1.25M Advance Investment Made In June 2026 Benzinga · June 2, 2026Pluri Announces Completion Of Development And U.S. Cosmetic Product Listings For Two Flagship Regenerative Aesthetic Products, Regenativo+ And Placento+, Clearing Way For U.S. Commercial Launch Benzinga · February 18, 2026Pluri Subsidiary Puri Biotech Secures Patent Covering 3D Immune Cell Expansion Tech Benzinga · February 12, 2026Pluri Q2 EPS $(0.71) Misses $(0.65) Estimate, Sales $198.000K Miss $638.000K Estimate Benzinga · January 22, 2026Pluri Completes First Phase Of Its Program With Resbiomed Technologies OOD Over Placenta-Derived Processing, Bioprocessing Capabilities Benzinga · December 22, 2025Pluri Expands Manufacturing Agreement With Remedy Cell, Advances Clinical-Grade Production Benzinga · December 9, 2025Pluri Appoints Alejandro Weinstein As Chairman